Icahn School of Medicine at Mount Sinai

Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.

The phase 2 TRANQUILITY trial found the IL-6 antibody pacibekitug produced sustained, dose-dependent reductions in hs-CRP in patients with chronic kidney disease.

Saakshi Khattri, MD, discusses a new JAAD dual Th17/type 2 signature study and what it means for personalized psoriasis care this Awareness Month.

Saakshi Khattri, MD, discusses new oral psoriasis options and AAD 2026 weight-loss combination-therapy data in psoriatic disease.

Saakshi Khattri, MD, discusses mental health screening gaps in psoriasis and a new Th17/type 2 immune signature study pointing toward personalized care.

Saakshi Khattri, MD, discusses oral TYK2 inhibitor and IL-23 antagonist data alongside weight-loss combination therapy reshaping psoriasis and PsA care.

PFAS found in cord blood linked to childhood gut inflammation and IBD risk; Elizabeth Spencer, MD, explains what it means for patients.

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, detailed how JAK inhibitors and oral minoxidil are reshaping hair loss treatment strategy.

This segment of Lio's RAD Conference interview in Nashville highlights the growing number of therapeutics and an increasingly personalized approach.

Peter Lio, MD, spoke at the RAD 2026 conference about the upcoming AAD pediatric guidelines for atopic dermatitis.

Payel Gupta, MD, discusses how IgE, FeNO, and type 2 comorbidities inform biologic choice and when a lack of response warrants switching agents.

Chung, MD, explains why sparsentan remains valuable in FSGS despite a negative eGFR endpoint.

Oren Cohen, MD, discusses his research and points toward more clinically deployable cardiovascular risk tools for patients with OSA.

Lee discusess DDW 2026 data linking binge drinking frequency to advanced hepatic fibrosis in SLD.

Colombel discusses long-term LUCENT extension data showing durable clinical, endoscopic, and histologic outcomes with mirikizumab in moderately to severely active UC.

1-year results from ASPIRE-CD suggest risankizumab (Skyrizi) improves HRQL, well-being, and treatment satisfaction in adults with Crohn's Disease.

Stephanie Gold, MD, explains prospective IBD-Metabolic Clinic data show GLP-1 RAs are safe and effective for weight management in IBD, with added benefits for bowel function and fatigue.

Marla Dubinsky, MD, explains LIBERTY post hoc data showing SC infliximab 240 mg recaptured clinical response within 8 weeks in CD and UC patients following a drug holiday.

Laurie Keefer, PhD, makes the case for integrating mental health, social determinants, and brain-gut behavior therapies into routine GI care.

APOL1 research is driving precision nephrology, but prediction gaps and equity challenges still limit clinical impact.

Experts call for greater awareness, improved collaboration with OB/GYNs, and more proactive MASLD screening strategies for women.

Experts discuss how metabolic and hormonal factors in women influence MASLD risk, progression, and potential long-term outcomes.

Hosts are joined by Meena Bansal, MD, to discuss long-standing research gaps and what clinicians need to understand about sex-specific drivers of liver disease today.

Evidence from 3 recent studies explores microbiome modulation, early allergen exposure, and immune tolerance as pathways for food allergy prevention.

Early allergen introduction, microbiome research, and immune programming studies suggest food allergy prevention may begin during infancy.

Phase 2 data presented at ADAA 2026 suggest azetukalner may improve anhedonia in MDD, even though the trial did not meet its primary neuroimaging endpoint.

Deep learning applied to routine ECGs identifies subtle cardiac signals linked to early COPD, potentially enabling earlier diagnosis and intervention.

Deep learning applied to routine ECGs identified COPD up to 15 months earlier, supporting earlier intervention and risk stratification strategies.

At AAAAI 2026, Lebwohl discussed REMIX trial data showing oral remibrutinib reduced CSU symptoms within 12 hours and improved disease control.

Using race-neutral spirometry equations such as GLI 2012 and GLI 2022 may improve diagnostic accuracy and reduce disparities in lung disease assessment.